TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36478142
Drug: BI 187004
Normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 187004 (20, 80 or 240 mg) as monotherapy
Study: 36478142
Drug: BI 187004
Normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 187004 (240 mg) in combination with metformin
Study: 36478142
Drug: BI 187004
Normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 187004 treatment
Study: 32773602
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA), median maximal tolerated dose 1663 mg/day
Study: 35534443
Drug: Lactobacillus complex
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus complex capsules (probiotics group)
Study: 35534443
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin only (control group)
Study: 32875383
Drug: DEX 8
Normalized name: Precedex 80 MCG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX 8 mg plus ETO 300 mg (DEX + ETO)
Study: 32875383
Drug: DEX 8
Normalized name: Precedex 80 MCG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX 8 mg (DEX)
Study: 32875383
Drug: ETO 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETO 300 mg (ETO)
Study: 32875383
Drug: Control (Paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Paracetamol 750 mg as rescue analgesics)
Study: 35409460
Drug: Masticatory Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masticatory Muscle Training (MaMuT) - part 1: three physiotherapeutic treatments and daily home exercises; part 2: daily home exercises only
Study: 35851507
Drug: High-dose Vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Vitamin B6 supplementation
Study: 35851507
Drug: High-dose Vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Vitamin B12 supplementation
Study: 32899045
Drug: Qishe pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qishe pill
Study: 33675351
Drug: High-dose FA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose FA (4.0 mg daily)
Study: 33675351
Drug: Low-dose FA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose FA (≤1.1 mg daily)
Study: 36401223
Drug: Lower BW
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower BW (≤ 2500 g)
Study: 36401223
Drug: Normal BW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal BW (2500 g < BW ≤ 3500 g)
Study: 36401223
Drug: Higher BW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher BW (> 3500 g)
Study: 32040379
Drug: Quadrivalent cell-based
Normalized name: Fluarix Quadrivalent 2018-2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent cell-based influenza vaccine (QIVc)
Study: 32343211
Drug: Tablet-based ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based ultrasound (US) for assessing bone age
Study: 36329602
Drug: 15 g of
Normalized name: magnesium hydroxide
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 g of almond paste and 4 g of inulin
Study: 32430429
Drug: Total antibody
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total antibody (Ab)
Study: 33414406
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g tryptophan (Trp-3)
Study: 33414406
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g tryptophan (Trp-1.5)
Study: 34180838
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care protocol implemented by GPs and nurse practitioners
Study: 36001498
Drug: XEN gel
Normalized name: XEN-2174
DrugBank: XEN-2174 (DB05012)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XEN gel stent
Study: 33377980
Drug: Remote activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote activity monitoring (RAM) system; details on dosage and duration not available.
Study: 32551912
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet containing background Se only (0.189 mg/kg; C)
Study: 32551912
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level sodium selenite (0.376 mg/kg; LSS)
Study: 32551912
Drug: High level
Normalized name: SODIUM CHLORIDE 5 g in 100 mL TOPICAL LIQUID [SDG high level disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High level sodium selenite (0.558 mg/kg; HSS)
Study: 32551912
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level commercial B Traxim® Se (0.244 mg/kg; LBT)
Study: 32551912
Drug: High level
Normalized name: SODIUM CHLORIDE 5 g in 100 mL TOPICAL LIQUID [SDG high level disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High level B Traxim® Se (0.448 mg/kg; HBT)
Study: 32551912
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level selenised yeast (0.290 mg/kg; LSY)
Study: 32551912
Drug: High level
Normalized name: SODIUM CHLORIDE 5 g in 100 mL TOPICAL LIQUID [SDG high level disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High level selenised yeast (0.487 mg/kg; HSY)
Study: 36195687
Drug: pepinemab antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: pepinemab antibody blockade of SEMA4D
Study: 34555149
Drug: Ibrexafungerp 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrexafungerp 300 mg BID for 1 day
Study: 34555149
Drug: Fluconazole 150
Normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 150 mg for 1 day
Study: 35990072
Drug: ABMT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABMT with real self-administered tDCS
Study: 35990072
Drug: ABMT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABMT with sham self-administered tDCS
Study: 38606174
Drug: Pharmacist-led medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led medication reconciliation
Study: 35921643
Drug: Polypharmacy (use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypharmacy (use of >4 drugs daily)
Study: 34759547
Drug: Fentanyl 2
Normalized name: fentanyl 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 2 µg/kg i.v.
Study: 34759547
Drug: Nalbuphine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 0.2 mg/kg i.v.
Study: 35197106
Drug: Mobile technology‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile technology‐based intervention including a personalized website, Fitbit activity tracker and app, individually tailored text messages based on Fitbit data, and daily intervention content on Instagram for 6 months
Study: 33536672
Drug: Timeliness of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timeliness of treatment initiation
Study: 33232658
Drug: 0.25% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% ropivacaine with 0.5 mcg/kg clonidine (RC group)
Study: 33232658
Drug: 0.25% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% ropivacaine with 0.1 mg/kg dexamethasone (RD group)
Study: 32608944
Drug: Electric toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electric toothbrush ("Oral‐B Pro‐Expert, «Procter & Gamble», USA)
Study: 33904591
Drug: Group assignment
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group assignment (treatment or wait-list control)
Study: 34514598
Drug: Etesevimab 1400
Normalized name: Etesevimab
DrugBank: Etesevimab (DB15897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etesevimab 1400 mg
Study: 34252915
Drug: DFN-15 62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFN-15 62.5 mg
Study: 34252915
Drug: DFN-15 125
Normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 5 g in 100 mL TOPICAL LOTION [DFNDR SUNSCREEN SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFN-15 125 mg
Study: 34252915
Drug: DFN-15 250
Normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 5 g in 100 mL TOPICAL LOTION [DFNDR SUNSCREEN SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFN-15 250 mg
Study: 33292826
Drug: Parent-administered pediatric
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-administered pediatric tuina
Study: 34107152
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia (TIVA) with propofol
Study: 34107152
Drug: Sevoflurane (SEVO)
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane (SEVO) inhaled anaesthesia
Study: 35507017
Drug: MEDI0680 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI0680 (20 mg/kg) with durvalumab (750 mg)
Study: 35507017
Drug: Nivolumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (240 mg)
Study: 35227582
Drug: Repetitive Transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) after a three-week induction treatment and six months of maintenance treatment (three-week periodicity)
Study: 33938081
Drug: Polish surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polish surface treatment
Study: 33938081
Drug: Optiglaze surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optiglaze surface treatment
Study: 33938081
Drug: Polish surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polish surface treatment (all immersion liquids)
Study: 33938081
Drug: Optiglaze surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optiglaze surface treatment (artificial saliva, tea, and wine)
Study: 35201358
Drug: Fentanyl (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1 μg/kg intravenous)
Study: 32459005
Drug: Zoledronate (ZOL)
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronate (ZOL) administered 6 months after last denosumab injection (6M group, n = 20)
Study: 32459005
Drug: Zoledronate (ZOL)
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronate (ZOL) administered 9 months after last denosumab injection (9M group, n = 20)
Study: 32459005
Drug: Zoledronate (ZOL)
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronate (ZOL) administered when bone turnover had increased (OBS group, n = 21)
Study: 33649927
Drug: Vaginal wall
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal wall injection
Study: 35981118
Drug: Mindfulness-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based intervention (MBI), 8-week personalized yoga therapy.
Study: 33704052
Drug: Orally disintegrating
Normalized name: Clozapine Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally disintegrating film of varenicline salicylate (test drug)
Study: 33704052
Drug: Film‐coated tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film‐coated tablets of varenicline tartrate (reference drug)
Study: 32717999
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg mango leaf extract (Zynamite®)
Study: 35389303
Drug: Calendula officinalis
Normalized name: Calendula officinalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calendula officinalis L.
Study: 32967390
Drug: Intradiscal ozone
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiscal ozone therapy (Group 1)
Study: 32967390
Drug: Intradiscal ozone
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiscal ozone therapy with periforaminal steroid injection (Group 2)
Study: 36172861
Drug: Quarterly antibiotic-prescribing
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quarterly antibiotic-prescribing feedback reports
Study: 33871558
Drug: LEU-PRO (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEU-PRO (3 g leucine, 10 g protein; n=38)
Study: 33871558
Drug: LEU-PRO+n-3 (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEU-PRO+n-3 (0.8 g EPA, 1.1 g DHA; n=38)
Study: 34871570
Drug: Tafenoquine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine 300 mg
Study: 35596578
Drug: THC (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (8 mg)
Study: 33048249
Drug: Deep learning
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep learning algorithm predicting ODI after treatment
Study: 33048249
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of actual patient values after 6 months with predictions for alternative therapy
Study: 32332590
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy with music (CBT-music)
Study: 33400421
Drug: Nutrafol® Women’s
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrafol® Women’s Balance Capsules
Study: 35822412
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg esomeprazole magnesium (test)
Study: 35822412
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg esomeprazole magnesium (reference)
Study: 35822412
Drug: Esomeprazole administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole administered while fed
Study: 32853704
Drug: Treatment intensity
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment intensity (25 hours per week)
Study: 32853704
Drug: Treatment intensity
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment intensity (15 hours per week)
Study: 33001255
Drug: Daily probiotic
Normalized name: CVS Daily Probiotic Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily probiotic group (Lactobacillus paracasei SD1 once daily)
Study: 33074709
Drug: Tauroursodeoxycholic acid
Normalized name: tauroursodeoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tauroursodeoxycholic acid (TUDCA) 1,500 mg
Study: 36389724
Drug: Anti-PD-1 adjuvant
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 adjuvant therapy (intravenous injection of 200 mg, repeated every 3 weeks for a total of 4 or 8 cycles)
Study: 36389724
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no anti-PD-1 therapy)
Study: 36389724
Drug: Anti-PD-1 adjuvant
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 adjuvant therapy
Study: 35136033
Drug: First-generation antipsychotics
Normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation antipsychotics (haloperidol or perphenazine)
Study: 35136033
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PRS and clinical data
Study: 33166719
Drug: Camrelizumab 200
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab 200 mg every 2 weeks plus apatinib 375 mg once daily (QD), 5 days on and 2 days off
Study: 35707974
Drug: 500‐mL intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500‐mL intravenous fluid bolus
Study: 33657849
Drug: Combined Intravenous
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Intravenous Thrombolysis (IVT) and Mechanical Thrombectomy (MT)
Study: 32045493
Drug: TAK-079 (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-079 (0.06 mg/kg i.v.)
Study: 32045493
Drug: TAK-079 (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-079 (0.6 mg/kg s.c.)
Study: 32045493
Drug: TAK-079 (≥0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-079 (≥0.3 mg/kg s.c.)
Study: 36076211
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric carboxymaltose (1000 mg dose at enrolment)
Study: 36076211
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulphate (195 mg elemental iron daily, thrice daily from enrolment till 6 weeks postpartum)
Study: 32499262
Drug: NAVIGATE intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NAVIGATE intervention (individualised medication management, individual resiliency training, supported employment and education, family education)
Study: 35879178
Drug: BoNTA (5U/0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNTA (5U/0.05 mL)
Study: 32253271
Drug: High-dose IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IV iron
Study: 32253271
Drug: Low-dose IV
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IV iron
Study: 34158778
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (2 gr) over 30 minutes
Study: 32517660
Drug: Natural rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural rectal progesterone (800 mg daily)
Study: 34241801
Drug: Buxue Yimu
Normalized name: Buxus Chinensis Oil
DrugBank: Jojoba oil (DB14252)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buxue Yimu Pills (BYP, 24 g/d)
Study: 34241801
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BYP and FS (BYP, 24 g/d plus FS Tablets, 0.9 g/d)
Study: 35235002
Drug: Fingolimod-discontinuation group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod-discontinuation group
Study: 32319006
Drug: BZD tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BZD tapering
Study: 32319006
Drug: Pharmaceutical GHB
Normalized name: GHB
DrugBank: gamma-Hydroxybutyric acid (DB01440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical GHB tapering
Study: 35817643
Drug: 3 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 sessions of radial extracorporeal shockwave therapy (rESWT)
Study: 35817643
Drug: minimal-dose rESWT
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: minimal-dose rESWT
Study: 33382448
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (3×1000 mg/day, 0.5 mEq/kg)
Study: 33382448
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride (2×1000 mg/day)
Study: 32162274
Drug: Remogliflozin etabonate
Normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remogliflozin etabonate 100 mg BID
Study: 34301751
Drug: Ramucirumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab (10 mg/kg) plus Erlotinib (150 mg/day)
Study: 39622410
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus Erlotinib (150 mg/day)
Study: 36201089
Drug: Biweekly TAS-102
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biweekly TAS-102 (35 mg/m2 twice daily on days 1-5 and 15-19 in a 4-week cycle) and bevacizumab (5 mg/kg every 2 weeks)
Study: 33856729
Drug: Flaxseed supplementation
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed supplementation (30 g/day ground flaxseed powder)
Study: 32576131
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion 0.25 μg/kg/min
Study: 32576131
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion 1ug/kg/min with propofol 50-150 ug/kg/min
Study: 36056577
Drug: PSA <
Normalized name: Prostate-Specific Antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA < 1 ng/mL
Study: 36056577
Drug: PSA 1.0-1.99
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA 1.0-1.99 ng/mL
Study: 36056577
Drug: PSA 2-2.99
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA 2-2.99 ng/mL
Study: 33540206
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy – Cognitive Therapy version (CPT-C)
Study: 35555185
Drug: Acipimox (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (50 mg/kg/day)
Study: 32757413
Drug: Nabilone (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone (median dose = 0.75 mg)
Study: 35487685
Drug: Increase of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase of 5.1 pg/mL in sNfL levels between baseline and 6 years
Study: 34932107
Drug: Multiorgan focused
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiorgan focused clinical ultrasonography (FCU) performed by an internal medicine physician in addition to standard clinical evaluation
Study: 33144354
Drug: Intensive glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glucose treatment
Study: 2011528253
Drug: Monochromatic infrared
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monochromatic infrared energy (MIRE) therapy, daily for a total of 12 treatments
Study: 32309857
Drug: HP rs2000999
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP rs2000999 G allele
Study: 33527576
Drug: L-menthol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-menthol (160 mg)